CN113980003B - 2- ((2-methoxyphenyl) sulfonyl) isoindoline compound and preparation method thereof - Google Patents
2- ((2-methoxyphenyl) sulfonyl) isoindoline compound and preparation method thereof Download PDFInfo
- Publication number
- CN113980003B CN113980003B CN202111637054.5A CN202111637054A CN113980003B CN 113980003 B CN113980003 B CN 113980003B CN 202111637054 A CN202111637054 A CN 202111637054A CN 113980003 B CN113980003 B CN 113980003B
- Authority
- CN
- China
- Prior art keywords
- compound
- cancer
- mmol
- reaction
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 2- ((2-methoxyphenyl) sulfonyl) isoindoline compound Chemical class 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 150000001875 compounds Chemical class 0.000 claims abstract description 70
- 150000003839 salts Chemical class 0.000 claims abstract description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 15
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 13
- 239000011435 rock Substances 0.000 claims abstract description 9
- 239000003112 inhibitor Substances 0.000 claims abstract description 8
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 6
- 201000010099 disease Diseases 0.000 claims abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 6
- 208000012902 Nervous system disease Diseases 0.000 claims abstract description 5
- 230000003176 fibrotic effect Effects 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 4
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims abstract description 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims abstract description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims abstract 2
- 125000001153 fluoro group Chemical group F* 0.000 claims abstract 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims abstract 2
- 238000006243 chemical reaction Methods 0.000 claims description 91
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 46
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 32
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 27
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 20
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 18
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 17
- 239000002904 solvent Substances 0.000 claims description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 claims description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 6
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 6
- 239000003054 catalyst Substances 0.000 claims description 6
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 claims description 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 6
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 claims description 5
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 claims description 5
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 claims description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 238000005859 coupling reaction Methods 0.000 claims description 4
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 239000001632 sodium acetate Substances 0.000 claims description 4
- 235000017281 sodium acetate Nutrition 0.000 claims description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 claims description 3
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 claims description 3
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 claims description 3
- 235000011181 potassium carbonates Nutrition 0.000 claims description 3
- 229910000160 potassium phosphate Inorganic materials 0.000 claims description 3
- 235000011009 potassium phosphates Nutrition 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- 238000003786 synthesis reaction Methods 0.000 claims description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 claims description 2
- 206010001413 Adult T-cell lymphoma/leukaemia Diseases 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 208000025966 Neurological disease Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 206010062129 Tongue neoplasm Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 230000009471 action Effects 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 206010027191 meningioma Diseases 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 230000002194 synthesizing effect Effects 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 201000006134 tongue cancer Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 230000002485 urinary effect Effects 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 230000003140 astrocytic effect Effects 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 51
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical group [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 44
- 238000004809 thin layer chromatography Methods 0.000 description 30
- 239000007787 solid Substances 0.000 description 28
- 238000004440 column chromatography Methods 0.000 description 27
- 239000012044 organic layer Substances 0.000 description 27
- 229910052763 palladium Inorganic materials 0.000 description 17
- 238000000605 extraction Methods 0.000 description 13
- 238000001035 drying Methods 0.000 description 11
- HIHOEGPXVVKJPP-JTQLQIEISA-N 5-fluoro-2-[[(1s)-1-(5-fluoropyridin-2-yl)ethyl]amino]-6-[(5-methyl-1h-pyrazol-3-yl)amino]pyridine-3-carbonitrile Chemical compound N([C@@H](C)C=1N=CC(F)=CC=1)C(C(=CC=1F)C#N)=NC=1NC=1C=C(C)NN=1 HIHOEGPXVVKJPP-JTQLQIEISA-N 0.000 description 10
- 238000001914 filtration Methods 0.000 description 10
- 238000012544 monitoring process Methods 0.000 description 10
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 10
- 238000010791 quenching Methods 0.000 description 10
- HPKJGHVHQWJOOT-ZJOUEHCJSA-N N-[(2S)-3-cyclohexyl-1-oxo-1-({(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}amino)propan-2-yl]-1H-indole-2-carboxamide Chemical compound C1C(CCCC1)C[C@H](NC(=O)C=1NC2=CC=CC=C2C=1)C(=O)N[C@@H](C[C@H]1C(=O)NCC1)C=O HPKJGHVHQWJOOT-ZJOUEHCJSA-N 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 108010041788 rho-Associated Kinases Proteins 0.000 description 6
- 102000000568 rho-Associated Kinases Human genes 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 101000669917 Homo sapiens Rho-associated protein kinase 1 Proteins 0.000 description 4
- 101000669921 Homo sapiens Rho-associated protein kinase 2 Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 102100039313 Rho-associated protein kinase 1 Human genes 0.000 description 4
- 102100039314 Rho-associated protein kinase 2 Human genes 0.000 description 4
- 229940125782 compound 2 Drugs 0.000 description 4
- 229940126214 compound 3 Drugs 0.000 description 4
- 229940125898 compound 5 Drugs 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 229940124531 pharmaceutical excipient Drugs 0.000 description 4
- KAFZOLYKKCWUBI-HPMAGDRPSA-N (2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-3-amino-2-[[(2s)-2-[[(2s)-2-(3-cyclohexylpropanoylamino)-4-methylpentanoyl]amino]-5-methylhexanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide Chemical compound N([C@@H](CC(C)C)C(=O)N[C@@H](CCC(C)C)C(=O)N[C@@H](CN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(N)=O)C(=O)CCC1CCCCC1 KAFZOLYKKCWUBI-HPMAGDRPSA-N 0.000 description 3
- PHDIJLFSKNMCMI-ITGJKDDRSA-N (3R,4S,5R,6R)-6-(hydroxymethyl)-4-(8-quinolin-6-yloxyoctoxy)oxane-2,3,5-triol Chemical compound OC[C@@H]1[C@H]([C@@H]([C@H](C(O1)O)O)OCCCCCCCCOC=1C=C2C=CC=NC2=CC=1)O PHDIJLFSKNMCMI-ITGJKDDRSA-N 0.000 description 3
- LDIOUQIXNSSOGU-UHFFFAOYSA-N 8-(3-pentylamino)-2-methyl-3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-5h-cyclopenta[d]pyrazolo[1,5-a]pyrimidine Chemical compound CC1=NN2C(NC(CC)CC)=C3CCCC3=NC2=C1C1=CC=C(OC)C=C1Cl LDIOUQIXNSSOGU-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- TZYWCYJVHRLUCT-VABKMULXSA-N N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Chemical compound CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 TZYWCYJVHRLUCT-VABKMULXSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- SRVFFFJZQVENJC-IHRRRGAJSA-N aloxistatin Chemical compound CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C SRVFFFJZQVENJC-IHRRRGAJSA-N 0.000 description 3
- OSVHLUXLWQLPIY-KBAYOESNSA-N butyl 2-[(6aR,9R,10aR)-1-hydroxy-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-3-yl]-2-methylpropanoate Chemical compound C(CCC)OC(C(C)(C)C1=CC(=C2[C@H]3[C@H](C(OC2=C1)(C)C)CC[C@H](C3)CO)O)=O OSVHLUXLWQLPIY-KBAYOESNSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 229940125773 compound 10 Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 3
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 2
- 229940126657 Compound 17 Drugs 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001450 anions Chemical group 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 150000001768 cations Chemical group 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 229940126142 compound 16 Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- HBENZIXOGRCSQN-VQWWACLZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylpentan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3[C@@]5(OC)CC[C@@]2([C@@]43CC1)C[C@@H]5[C@](C)(O)C(C)(C)CC)CC1CC1 HBENZIXOGRCSQN-VQWWACLZSA-N 0.000 description 1
- FANCTJAFZSYTIS-IQUVVAJASA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)CS(=N)(=O)C1=CC=CC=C1 FANCTJAFZSYTIS-IQUVVAJASA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- SHAHPWSYJFYMRX-GDLCADMTSA-N (2S)-2-(4-{[(1R,2S)-2-hydroxycyclopentyl]methyl}phenyl)propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C[C@@H]1[C@@H](O)CCC1 SHAHPWSYJFYMRX-GDLCADMTSA-N 0.000 description 1
- LJIOTBMDLVHTBO-CUYJMHBOSA-N (2s)-2-amino-n-[(1r,2r)-1-cyano-2-[4-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]phenyl]cyclopropyl]butanamide Chemical compound CC[C@H](N)C(=O)N[C@]1(C#N)C[C@@H]1C1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)N2CCN(C)CC2)C=C1 LJIOTBMDLVHTBO-CUYJMHBOSA-N 0.000 description 1
- VUDZSIYXZUYWSC-DBRKOABJSA-N (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one Chemical compound FC1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N[C@H](O)CC1 VUDZSIYXZUYWSC-DBRKOABJSA-N 0.000 description 1
- FRJJJAKBRKABFA-TYFAACHXSA-N (4r,6s)-6-[(e)-2-[6-chloro-4-(4-fluorophenyl)-2-propan-2-ylquinolin-3-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C(\[C@H]1OC(=O)C[C@H](O)C1)=C/C=1C(C(C)C)=NC2=CC=C(Cl)C=C2C=1C1=CC=C(F)C=C1 FRJJJAKBRKABFA-TYFAACHXSA-N 0.000 description 1
- VIMMECPCYZXUCI-MIMFYIINSA-N (4s,6r)-6-[(1e)-4,4-bis(4-fluorophenyl)-3-(1-methyltetrazol-5-yl)buta-1,3-dienyl]-4-hydroxyoxan-2-one Chemical compound CN1N=NN=C1C(\C=C\[C@@H]1OC(=O)C[C@@H](O)C1)=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 VIMMECPCYZXUCI-MIMFYIINSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- IGVKWAAPMVVTFX-BUHFOSPRSA-N (e)-octadec-5-en-7,9-diynoic acid Chemical compound CCCCCCCCC#CC#C\C=C\CCCC(O)=O IGVKWAAPMVVTFX-BUHFOSPRSA-N 0.000 description 1
- DPRJPRMZJGWLHY-HNGSOEQISA-N (e,3r,5s)-7-[5-(4-fluorophenyl)-3-propan-2-yl-1-pyrazin-2-ylpyrazol-4-yl]-3,5-dihydroxyhept-6-enoic acid Chemical compound OC(=O)C[C@H](O)C[C@H](O)/C=C/C=1C(C(C)C)=NN(C=2N=CC=NC=2)C=1C1=CC=C(F)C=C1 DPRJPRMZJGWLHY-HNGSOEQISA-N 0.000 description 1
- FWNUOCNNMOUWSK-UHFFFAOYSA-N 1-[2-[2-methoxy-4-(1H-pyrazol-4-yl)phenyl]sulfonyl-1,3-dihydroisoindol-5-yl]ethanone Chemical compound CC(C1=CC=C(CN(C2)S(C(C=CC(C3=CNN=C3)=C3)=C3OC)(=O)=O)C2=C1)=O FWNUOCNNMOUWSK-UHFFFAOYSA-N 0.000 description 1
- NQDGIOAEJSYWKX-UHFFFAOYSA-N 1-[2-[4-(1H-indazol-5-yl)-2-methoxyphenyl]sulfonyl-1,3-dihydroisoindol-5-yl]ethanone Chemical compound CC(C1=CC=C(CN(C2)S(C(C=CC(C3=CC=C4NN=CC4=C3)=C3)=C3OC)(=O)=O)C2=C1)=O NQDGIOAEJSYWKX-UHFFFAOYSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- AYJONLIISMYCGL-UHFFFAOYSA-N 2-(2-methoxyphenyl)sulfonyl-1,3-dihydroisoindole Chemical class COC(C=CC=C1)=C1S(N1CC2=CC=CC=C2C1)(=O)=O AYJONLIISMYCGL-UHFFFAOYSA-N 0.000 description 1
- HYAPQCXNTMLJQP-UHFFFAOYSA-N 2-[2-methoxy-4-(1H-pyrazol-4-yl)phenyl]sulfonyl-1,3-dihydroisoindole-4-carboxamide Chemical compound COC(C=C(C=C1)C2=CNN=C2)=C1S(N(CC1=CC=C2)CC1=C2C(N)=O)(=O)=O HYAPQCXNTMLJQP-UHFFFAOYSA-N 0.000 description 1
- LDFAAJQKUDVZFC-UHFFFAOYSA-N 2-[2-methoxy-4-(1H-pyrazol-4-yl)phenyl]sulfonyl-1,3-dihydroisoindole-5-carboxamide Chemical compound COC(C=C(C=C1)C2=CNN=C2)=C1S(N1CC2=CC(C(N)=O)=CC=C2C1)(=O)=O LDFAAJQKUDVZFC-UHFFFAOYSA-N 0.000 description 1
- UWQDCUDRCVOEPI-UHFFFAOYSA-N 2-[2-methoxy-4-(1H-pyrazol-4-yl)phenyl]sulfonyl-5-(trifluoromethyl)-1,3-dihydroisoindole Chemical compound COC(C=C(C=C1)C2=CNN=C2)=C1S(N1CC2=CC(C(F)(F)F)=CC=C2C1)(=O)=O UWQDCUDRCVOEPI-UHFFFAOYSA-N 0.000 description 1
- SQYBROOSOHCBMN-UHFFFAOYSA-N 2-[2-methoxy-4-(1H-pyrazol-4-yl)phenyl]sulfonyl-N,N-dimethyl-1,3-dihydroisoindol-5-amine Chemical compound CN(C)C1=CC=C(CN(C2)S(C(C=CC(C3=CNN=C3)=C3)=C3OC)(=O)=O)C2=C1 SQYBROOSOHCBMN-UHFFFAOYSA-N 0.000 description 1
- GQIAWVUVHDGJAM-UHFFFAOYSA-N 2-[4-(1H-indazol-5-yl)-2-methoxyphenyl]sulfonyl-1,3-dihydroisoindole-5-carboxamide Chemical compound COC(C=C(C=C1)C2=CC=C3NN=CC3=C2)=C1S(N1CC2=CC(C(N)=O)=CC=C2C1)(=O)=O GQIAWVUVHDGJAM-UHFFFAOYSA-N 0.000 description 1
- NPYNXKUTSGKJBO-UHFFFAOYSA-N 2-[4-(1H-indazol-5-yl)-2-methoxyphenyl]sulfonyl-N,N-dimethyl-2,3-dihydro-1H-indol-5-amine Chemical compound CN(C)C(C=C1C2)=CC=C1NC2S(C(C=CC(C1=CC=C2NN=CC2=C1)=C1)=C1OC)(=O)=O NPYNXKUTSGKJBO-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- KOALIOVUKPQQTI-UHFFFAOYSA-N 4-fluoro-2-[2-methoxy-4-(1H-pyrazol-4-yl)phenyl]sulfonyl-1,3-dihydroisoindole Chemical compound COC(C=C(C=C1)C2=CNN=C2)=C1S(N(CC1=CC=C2)CC1=C2F)(=O)=O KOALIOVUKPQQTI-UHFFFAOYSA-N 0.000 description 1
- IHMJHGFRBCRYTG-UHFFFAOYSA-N 4-methoxy-2-[2-methoxy-4-(1H-pyrazol-4-yl)phenyl]sulfonyl-1,3-dihydroisoindole Chemical compound COC1=C(CN(C2)S(C(C=CC(C3=CNN=C3)=C3)=C3OC)(=O)=O)C2=CC=C1 IHMJHGFRBCRYTG-UHFFFAOYSA-N 0.000 description 1
- TZKBVRDEOITLRB-UHFFFAOYSA-N 4-methyl-n-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[2-(1h-pyrazolo[3,4-b]pyridin-5-yl)ethynyl]benzamide Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2C=C3C=NNC3=NC=2)=C1 TZKBVRDEOITLRB-UHFFFAOYSA-N 0.000 description 1
- REYIAKRZWMSRON-UHFFFAOYSA-N 5-[3-methoxy-4-[(5-methoxy-1,3-dihydroisoindol-2-yl)sulfonyl]phenyl]-1H-indazole Chemical compound COC1=CC=C(CN(C2)S(C(C=CC(C3=CC=C4NN=CC4=C3)=C3)=C3OC)(=O)=O)C2=C1 REYIAKRZWMSRON-UHFFFAOYSA-N 0.000 description 1
- RWXIPFCVJNSQHQ-UHFFFAOYSA-N 5-[3-methoxy-4-[[5-(trifluoromethyl)-1,3-dihydroisoindol-2-yl]sulfonyl]phenyl]-1H-indazole Chemical compound COC(C=C(C=C1)C2=CC=C3NN=CC3=C2)=C1S(N1CC2=CC(C(F)(F)F)=CC=C2C1)(=O)=O RWXIPFCVJNSQHQ-UHFFFAOYSA-N 0.000 description 1
- FJVYNXSULPVJKQ-UHFFFAOYSA-N 5-[4-[(5-chloro-1,3-dihydroisoindol-2-yl)sulfonyl]-3-methoxyphenyl]-1H-indazole Chemical compound COC(C=C(C=C1)C2=CC=C3NN=CC3=C2)=C1S(N1CC2=CC(Cl)=CC=C2C1)(=O)=O FJVYNXSULPVJKQ-UHFFFAOYSA-N 0.000 description 1
- WXEUJDFWDYGMBN-UHFFFAOYSA-N 5-[4-[(5-fluoro-1,3-dihydroisoindol-2-yl)sulfonyl]-3-methoxyphenyl]-1H-indazole Chemical compound COC(C=C(C=C1)C2=CC=C3NN=CC3=C2)=C1S(N1CC2=CC(F)=CC=C2C1)(=O)=O WXEUJDFWDYGMBN-UHFFFAOYSA-N 0.000 description 1
- JTNRDTJILDITMV-UHFFFAOYSA-N 5-chloro-2-[2-methoxy-4-(1H-pyrazol-4-yl)phenyl]sulfonyl-1,3-dihydroisoindole Chemical compound COC(C=C(C=C1)C2=CNN=C2)=C1S(N1CC2=CC(Cl)=CC=C2C1)(=O)=O JTNRDTJILDITMV-UHFFFAOYSA-N 0.000 description 1
- RILXHXOYEKLPKI-UHFFFAOYSA-N 5-fluoro-2-[2-methoxy-4-(1H-pyrazol-4-yl)phenyl]sulfonyl-1,3-dihydroisoindole Chemical compound COC(C=C(C=C1)C2=CNN=C2)=C1S(N1CC2=CC(F)=CC=C2C1)(=O)=O RILXHXOYEKLPKI-UHFFFAOYSA-N 0.000 description 1
- RVOPNBZTUSZCON-UHFFFAOYSA-N 5-methoxy-2-[2-methoxy-4-(1H-pyrazol-4-yl)phenyl]sulfonyl-1,3-dihydroisoindole Chemical compound COC1=CC=C(CN(C2)S(C(C=CC(C3=CNN=C3)=C3)=C3OC)(=O)=O)C2=C1 RVOPNBZTUSZCON-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000005440 Basal Cell Neoplasms Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- QUMCIHKVKQYNPA-RUZDIDTESA-N C1(CCCCC1)CN1[C@@H](C=2N(C=3C=NC(=NC1=3)NC1=C(C=C(C(=O)NC3CCN(CC3)C)C=C1)OC)C(=NN=2)C)CC Chemical compound C1(CCCCC1)CN1[C@@H](C=2N(C=3C=NC(=NC1=3)NC1=C(C=C(C(=O)NC3CCN(CC3)C)C=C1)OC)C(=NN=2)C)CC QUMCIHKVKQYNPA-RUZDIDTESA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
- 108091006109 GTPases Proteins 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000005927 Myosarcoma Diseases 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010030043 Ocular hypertension Diseases 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102100028286 Proto-oncogene tyrosine-protein kinase receptor Ret Human genes 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000001286 intracranial vasospasm Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- XMSZANIMCDLNKA-UHFFFAOYSA-N methyl hypofluorite Chemical compound COF XMSZANIMCDLNKA-UHFFFAOYSA-N 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000002077 muscle cancer Diseases 0.000 description 1
- YOVNFNXUCOWYSG-UHFFFAOYSA-N n-[3-[2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethylimidazo[4,5-c]pyridin-6-yl]oxyphenyl]-4-(2-morpholin-4-ylethoxy)benzamide Chemical compound C1=C2N(CC)C(C=3C(=NON=3)N)=NC2=CN=C1OC(C=1)=CC=CC=1NC(=O)C(C=C1)=CC=C1OCCN1CCOCC1 YOVNFNXUCOWYSG-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000003590 rho kinase inhibitor Substances 0.000 description 1
- QSKQVZWVLOIIEV-NSHDSACASA-N ripasudil Chemical compound C[C@H]1CNCCCN1S(=O)(=O)C1=CC=CC2=CN=CC(F)=C12 QSKQVZWVLOIIEV-NSHDSACASA-N 0.000 description 1
- 229950007455 ripasudil Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 201000009825 uterine corpus cancer Diseases 0.000 description 1
- JQSHBVHOMNKWFT-DTORHVGOSA-N varenicline Chemical compound C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 JQSHBVHOMNKWFT-DTORHVGOSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The invention relates to the technical field of medicaments, and provides a 2- ((2-methoxyphenyl) sulfonyl) isoindoline compound and a preparation method thereof. The 2- ((2-methoxyphenyl) sulfonyl) isoindoline compound is a compound with a structure shown in a formula I or a pharmaceutically acceptable salt thereof. The structure of the formula I is as follows:
wherein R is1Is methoxy, fluoro, chloro, bromo, cyano, aminocarbonyl, acetyl, dimethylamino, trifluoromethyl, R21H-indazol-5-yl and 1H-pyrazol-4-yl. The 2- ((2-methoxyphenyl) sulfonyl) isoindoline compound can be used as an effective ROCK inhibitor. The pharmaceutical composition containing the compound also has good pharmacological activity for treating tumors, cardiovascular diseases, nervous system diseases and fibrotic diseases.
Description
Technical Field
The invention relates to the technical field of medicines, in particular to a 2- ((2-methoxyphenyl) sulfonyl) isoindoline compound and a preparation method thereof.
Background
Rho belongs to small molecule single polymer GTPase superfamily, is a mammalian gene homolog of RAS superfamily, and regulates the recombination of a cell actin skeleton through a downstream most main effector Rho kinase, thereby widely participating in a series of biological processes such as cell mitosis, cytoskeleton regulation, nerve regeneration, tumor cell infiltration, apoptosis and the like. Rho kinase has now been found to be predominantly of two subtypes: ROCK1, the former being mainly present in non-neural tissues such as heart, lung, etc., and ROCK2, the latter being mainly present in the central nervous system such as neurons, cerebral cortex, etc.
Rho is abnormally activated in a variety of cardiovascular diseases, such as atherosclerosis, hypertension, pulmonary hypertension, and the like. Rho inhibitors exhibit benefits in the treatment of these diseases in animal models. In addition, there is evidence that inhibition of Rho kinase activation in vivo also has the effects of promoting neuronal synapse growth and promoting recovery of neurological function following injury, and can be used for treating and alleviating central nervous diseases such as spinal cord injury, Alzheimer's disease, and neuroinflammation, spinal cord demyelination. In addition, tumor infiltration and migration are also dependent on Rho kinase activation, inhibition of Rho kinase activation also inhibits tumor metastasis.
The only ROCK inhibitors currently on the market are erl (for the treatment of cerebral vasospasm) and Glanatec (for the treatment of ocular hypertension and glaucoma). Therefore, the development of the ROCK inhibitor with novel structure and strong activity has important significance.
Disclosure of Invention
In order to search for a novel ROCK inhibitor, the invention designs and synthesizes a series of 2- ((2-methoxyphenyl) sulfonyl) isoindoline compounds which have novel structures and high Rho kinase inhibition activity through extensive and intensive research, and the ROCK inhibition activity of the compounds is researched.
The invention aims to provide a 2- ((2-methoxyphenyl) sulfonyl) isoindoline compound or a pharmaceutically acceptable salt thereof.
Another object of the present invention is to provide a process for the preparation of the above compound.
It is another object of the present invention to provide a pharmaceutical composition comprising the above compound.
Another object of the present invention is to provide the use of the above compounds and the above pharmaceutical compositions as Rho kinase inhibitors for the treatment of tumors, cardiovascular diseases, neurological diseases, fibrotic diseases.
In order to realize the aim of the invention, the invention adopts the technical scheme that:
in a first aspect, the present invention provides a compound having the structure of formula i:
wherein R is1Is methoxy, fluorine, chlorine, bromine, cyano, aminocarbonyl, acetyl, dimethylamino, trifluoromethyl,
R21H-indazol-5-yl and 1H-pyrazol-4-yl.
The compound with the structure of formula I or the pharmaceutically acceptable salt thereof provided by the invention can be selected from the compounds with the structure of the following compounds:
in a second aspect, the present invention provides a process for the preparation of a compound having the structure of formula i or a pharmaceutically acceptable salt thereof, comprising the steps of:
and (3) synthesizing an intermediate IV:
reacting a compound II with a structure shown in a formula II and a compound III with a structure shown in a formula III in a first solvent in the presence of a first base at a first reaction temperature to generate an intermediate IV with a structure shown in a formula IV;
synthesis of Compound I:
and (3) carrying out coupling reaction on the intermediate IV and the compound V with the structure of the formula V in a second solvent in the presence of a second base under the action of a catalyst at a second reaction temperature to generate the compound with the structure of the formula I.
As a preferable embodiment of the preparation method provided by the present invention, the first solvent is at least one of tetrahydrofuran, dioxane, toluene, N-dimethylformamide, dichloromethane, and acetonitrile;
and/or the second solvent is any one of dioxane, N-dimethylformamide, toluene, dioxane/water and glycol dimethyl ether.
As another preferable embodiment of the preparation method provided by the present invention, the first reaction temperature is 20 to 100 ℃;
and/or the second reaction temperature is 40-120 ℃.
As another preferable embodiment of the preparation method provided by the present invention, the first base is at least one of triethylamine, N-diisopropylethylamine, N-methylmorpholine, potassium carbonate, cesium carbonate, and sodium carbonate;
and/or the second base is at least one of cesium carbonate, sodium tert-butoxide, potassium carbonate, sodium acetate and potassium phosphate.
As another preferable embodiment of the preparation method provided by the present invention, the catalyst is palladium tetratriphenylphosphine (Pd (PPh)3)4) Palladium acetate (Pd (OAc)2) Tris (dibenzylideneacetone) dipalladium (Pd)2(dba)3) 1,1' -bis (diphenylphosphino) ferrocene dichloropalladium (Pd) (dppf) Cl2) At least one of
The preparation method provided by the invention takes a compound II and a compound III as initial raw materials, firstly synthesizes an intermediate IV, and then carries out coupling reaction on the intermediate IV and a compound V to prepare the compound with the structure of a formula I. The whole preparation process is simple to operate, easy to control, low in requirements on production equipment and suitable for industrial large-scale production.
In a third aspect, the present invention provides a pharmaceutical composition comprising a compound having the structure of formula i, or a pharmaceutically acceptable salt thereof.
In the present invention, a compound having the structure of formula i or a pharmaceutically acceptable salt thereof is a pharmaceutically active ingredient in a pharmaceutical composition.
The present invention provides pharmaceutical compositions comprising, in addition to a therapeutically effective amount of at least one compound having the structure of formula i:
one or more pharmaceutical excipients;
and/or one or more pharmaceutically active substances having ROCK inhibitory activity other than the compound having the structure of formula i or a pharmaceutically acceptable salt thereof.
Methods of preparing the pharmaceutical compositions provided herein will be apparent to those skilled in the art and include conventional mixing, dissolving, lyophilizing and like techniques.
The pharmaceutical composition provided by the invention can be prepared into various common dosage forms, such as tablets, pills, capsules, granules, oral solutions, oral suspensions, oral emulsions, injections and the like, according to conventional preparation methods in the pharmaceutical field. It is convenient to provide the patient with clinical use by administering to the patient by various common modes of administration, such as oral or parenteral administration (by intravenous, intramuscular, topical or subcutaneous routes).
In a fourth aspect, the invention provides a compound having a structure shown in formula I, a pharmaceutically acceptable salt thereof and application of a pharmaceutical composition containing the compound having the structure shown in formula I and the pharmaceutically acceptable salt thereof as a ROCK inhibitor in preparation of medicines for treating tumors, cardiovascular diseases, nervous system diseases and fibrotic diseases.
Further, the tumor is selected from:
skin cancer, bladder cancer, ovarian cancer, breast cancer, stomach cancer, prostate cancer, colon cancer, lung cancer, bone cancer, brain cancer, rectal cancer, esophageal cancer, tongue cancer, kidney cancer, cervical cancer, corpus uteri cancer, testicular cancer, urinary cancer, melanoma, astrocytoma, meningioma, hodgkin's lymphoma, non-hodgkin's lymphoma, acute lymphatic leukemia, chronic lymphatic leukemia, acute myeloid leukemia, chronic myeloid leukemia, adult T-cell leukemia lymphoma, hepatocellular carcinoma, multiple myeloma, basal cell tumor, seminoma, chondrosarcoma, myosarcoma, fibrosarcoma.
Some of the terms involved in the expression of the present invention are defined as follows:
the term "pharmaceutically acceptable salts" refers to those salts that retain the biological effectiveness and properties of the parent compound. The salt comprises:
acid addition salts obtained by reaction of the free base of the parent compound with an inorganic acid or with an organic acid; the inorganic acid comprises hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, phosphoric acid, sulfuric acid, perchloric acid and the like; the organic acid includes acetic acid, oxalic acid, (D) or (L) malic acid, maleic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, tartaric acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, fumaric acid, gluconic acid, glutamic acid, isethionic acid, lactic acid, mandelic acid, mucic acid, pamoic acid, pantothenic acid, succinic acid, malonic acid, or the like; preferably hydrochloric acid or (L) -malic acid;
or, a salt formed when an acid proton present in the parent compound is replaced with a metal ion or coordinated with an organic base; the metal ions include alkali metal ions, alkaline earth ions, aluminum ions and the like; the organic base includes ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, etc.
The term "hydrate" refers to a substance in which water molecules are coordinately or covalently bound to cations or anions in a compound, or to a substance in which water ions are not directly bound to cations or anions but exist at certain positions in a solid crystal lattice in a certain proportion.
The term "solvate" refers to a substance formed by association of a compound with molecules of a pharmaceutically acceptable solvent, which typically includes ethanol, acetic acid, and the like.
The term "stereoisomer" refers to compounds having the same molecular formula, but differing in the arrangement of the atoms in the molecule in space. Since the compounds provided by the present invention may have one or more asymmetric centers, the compounds may be prepared as (R) -stereoisomers alone or (S) -stereoisomers alone or as mixtures thereof. Unless otherwise indicated, the description or designation of a particular compound in this invention is intended to include the individual enantiomers and racemic or other mixtures thereof. Methods for determining stereochemical configuration and separating stereoisomers are routine in the art (see the discussion in chapter 4 of Ad V attached Organic Chemistry, 4 th edition, J.March, John Wiley and Sons, New York, 1992). Thus, the present invention also encompasses any stereoisomeric form, its corresponding enantiomers (d-and l-or (+) and (-) isomers) and diastereomers thereof and mixtures thereof, having the ability to modulate RET kinase activity, and is not limited to any one stereoisomeric form.
The term "pharmaceutical composition" refers to a mixture of one or more of the compounds provided herein with other chemical ingredients (e.g., pharmaceutical excipients). The purpose of the pharmaceutical composition is to facilitate the administration of the compound to the organism.
The term "pharmaceutical excipient" refers to a substance that has been reasonably evaluated in terms of safety, does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the compound administered, and is included in a pharmaceutical preparation, in addition to an active ingredient. The pharmaceutic adjuvant has important functions of solubilization, dissolution assistance, sustained and controlled release and the like besides excipient, carrier and stability improvement, and is an important component which may influence the quality, safety and effectiveness of the pharmaceutical composition. The pharmaceutical excipients include, but are not limited to, carriers, diluents, excipients, solubilizers, binders, disintegrants, penetration enhancers, pH adjusters, buffers, release retardants, flavoring agents, preservatives, antioxidants, and the like.
The invention has the beneficial effects that:
(1) the invention provides a 2- ((2-methoxyphenyl) sulfonyl) isoindoline compound or a pharmaceutically acceptable salt thereof, which can be used as an effective ROCK inhibitor and has stronger inhibitory activity.
(2) The invention also provides a pharmaceutical composition containing the 2- ((2-methoxyphenyl) sulfonyl) isoindoline compound or pharmaceutically acceptable salt thereof, which has good pharmacological activity for treating tumors, cardiovascular diseases, nervous system diseases and fibrotic diseases.
Detailed Description
In order to make the technical problems, technical solutions and advantageous effects to be solved by the present invention more apparent, the present invention is described in further detail below with reference to specific embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the present patent and do not limit the scope of the invention in any way.
In the preparation method of the compound with the structure of formula I or the pharmaceutically acceptable salt thereof, the specific reaction process is as follows:
in the first step, intermediate IV is synthesized: dissolving a compound II, a compound III and a first base in a first solvent, and reacting at 20-100 ℃ to generate an intermediate IV.
Wherein the first base can be at least one selected from triethylamine, N-diisopropylethylamine, N-methylmorpholine, potassium carbonate, cesium carbonate and sodium carbonate.
The first solvent may be at least one selected from tetrahydrofuran, dioxane, toluene, N-dimethylformamide, dichloromethane, and acetonitrile.
For example, 1mol of compound II, 1mol of compound III and 1.5mol of N, N-diisopropylethylamine are dissolved in 5L of tetrahydrofuran and the reaction is stirred at 40 ℃ to give intermediate IV. The reaction can be monitored by Thin Layer Chromatography (abbreviated as TLC), and after the reaction is finished, the intermediate iv can be obtained by conventional processing techniques such as extraction, drying, concentration, separation and the like.
The second step is the synthesis of a compound having the structure of formula i: and dissolving the intermediate IV, the compound V, a second alkali and a catalyst in a second solvent, and performing coupling reaction at 40-120 ℃ to generate the compound with the structure of the formula I.
Wherein the second base is at least one selected from cesium carbonate, sodium tert-butoxide, potassium carbonate, sodium acetate and potassium phosphate.
The second solvent can be any one of dioxane, N-dimethylformamide, toluene, dioxane/water and ethylene glycol dimethyl ether.
The catalyst can be selected from palladium tetratriphenylphosphine (Pd (PPh)3)4) Palladium acetate (Pd (OAc)2) Tris (dibenzylideneacetone) dipalladium (Pd)2(dba)3) 1,1' -bis (diphenylphosphino) ferrocene dichloropalladium (Pd) (dppf) Cl2) At least one of (1).
For example, 1mol of intermediate IV, 1mol of compound V, 2mol of sodium acetate and 0.1mol of palladium acetate (Pd (OAc)2) Dissolving in 4L dioxane, and stirring at 75 deg.C to obtain the compound with structure of formula I. The reaction can be monitored by TLC, and after the reaction is finished, the final product can be obtained by conventional treatment processes such as concentration, separation and the like.
The invention is described in more detail by referring to a part of the tests, which are carried out in sequence, and the following detailed description is given by combining specific examples:
unless defined otherwise, technical terms used in the following examples have the same meanings as commonly understood by one of ordinary skill in the art to which the present invention belongs. The reagents used in the following examples, unless otherwise specified, are all conventional biochemical reagents; the raw materials, instruments, equipment and the like used in the following examples are either commercially available or available by existing methods; the dosage of the reagent is the dosage of the reagent in the conventional experiment operation if no special description exists; the experimental methods are conventional methods unless otherwise specified.
Example 1
5-methoxy-2- ((2-methoxy-4- (1H-pyrazol-4-yl) phenyl) sulfonyl) isoindoline
The first step is as follows:
dissolving compound 1a (2.84 g, 10.0 mmol), compound 1b (1.5 g, 10.0 mmol) and N, N-Diisopropylethylamine (DIEA) (1.9 g, 15.0 mmol) in dichloromethane (50 mL), reacting at room temperature, monitoring the reaction by TLC, adding water (50 mL) after the reaction is finished, quenching the reaction, drying the organic layer, filtering, concentrating, and separating by column chromatography to obtain 2.6g of light yellow solid (compound 1 c), wherein the yield is 65.5%;
the second step is that:
compound 1c (397 mg, 1.0 mmol), compound 1d (112 mg, 1.0 mmol), potassium carbonate (276 mg, 2.0 mmol), palladium tetrakistriphenylphosphine (Pd (PPh)3)4) (115 mg, 0.1 mmol) was dissolved in dioxane (30 mL) and water (10 mL), the reaction was stirred at 80 ℃ and monitored by TLC, after completion of the reaction, extraction was performed with ethyl acetate (50 mL. times.2), the organic layer was concentrated, and column chromatography was performed to give 224mg of off-white solid (Compound 1) in 58.2% yield. ESI (+) m/z = 386.1.
Example 2
5-fluoro-2- ((2-methoxy-4- (1H-pyrazol-4-yl) phenyl) sulfonyl) isoindoline
The first step is as follows:
dissolving compound 1a (2.84 g, 10.0 mmol), compound 2a (1.37 g, 10.0 mmol) and DIEA (1.9 g, 15.0 mmol) in dichloromethane (50 mL), reacting at room temperature, monitoring the reaction by TLC, adding water (50 mL) after the reaction to quench the reaction, drying the organic layer, filtering, concentrating, and separating by column chromatography to obtain a light yellow solid (compound 2 b) 2.7g with a yield of 70.3%;
the second step is that:
compound 2b (385 mg, 1.0 mmol), compound 1d (112 mg, 1.0 mmol), potassium carbonate (276 mg, 2.0 mmol), and tetratriphenylphosphine palladium (115 mg, 0.1 mmol) were dissolved in dioxane (30 mL) and water (10 mL), the reaction was stirred at 80 ℃, the reaction was monitored by TLC, after completion of the reaction, extraction was performed with ethyl acetate (50 mL × 2), the organic layer was concentrated, and column chromatography was performed to obtain 257mg of off-white solid (compound 2), with a yield of 68.9%. ESI (+) m/z = 374.1.
Example 3
5-chloro-2- ((2-methoxy-4- (1H-pyrazol-4-yl) phenyl) sulfonyl) isoindoline
The first step is as follows:
dissolving compound 1a (2.84 g, 10.0 mmol), compound 3a (1.5 g, 10.0 mmol) and DIEA (1.9 g, 15.0 mmol) in dichloromethane (50 mL), reacting at room temperature, monitoring the reaction by TLC, adding water (50 mL) after the reaction to quench the reaction, drying the organic layer, filtering, concentrating, and separating by column chromatography to obtain a light yellow solid (compound 3 b) 2.2g with a yield of 55.0%;
the second step is that:
compound 3b (400 mg, 1.0 mmol), compound 1d (112 mg, 1.0 mmol), potassium carbonate (276 mg, 2.0 mmol), and tetratriphenylphosphine palladium (115 mg, 0.1 mmol) were dissolved in dioxane (30 mL) and water (10 mL), the reaction was stirred at 80 ℃, the reaction was monitored by TLC, after completion of the reaction, extraction was performed with ethyl acetate (50 mL × 2), the organic layer was concentrated, and column chromatography was performed to obtain 209mg of off-white solid (compound 3), with a yield of 53.6%. ESI (+) m/z = 390.1.
Example 4
5-dimethylamino-2- ((2-methoxy-4- (1H-pyrazol-4-yl) phenyl) sulfonyl) isoindoline
The first step is as follows:
dissolving compound 1a (2.84 g, 10.0 mmol), compound 4a (1.6 g, 10.0 mmol) and DIEA (1.9 g, 15.0 mmol) in dichloromethane (50 mL), reacting at room temperature, monitoring the reaction by TLC, adding water (50 mL) after the reaction to quench the reaction, drying the organic layer, filtering, concentrating, and separating by column chromatography to obtain a light yellow solid (compound 4 b) 1.9g with a yield of 46.3%;
the second step is that:
compound 4b (410 mg, 1.0 mmol), compound 1d (112 mg, 1.0 mmol), potassium carbonate (276 mg, 2.0 mmol), and tetratriphenylphosphine palladium (115 mg, 0.1 mmol) were dissolved in dioxane (30 mL) and water (10 mL), the reaction was stirred at 80 ℃, the reaction was monitored by TLC, after completion of the reaction, extraction was performed with ethyl acetate (50 mL × 2), the organic layer was concentrated, and column chromatography was performed to obtain an off-white solid (compound 4) 252mg, with a yield of 63.3%. ESI (+) m/z = 399.1.
Example 5
5-acetyl-2- ((2-methoxy-4- (1H-pyrazol-4-yl) phenyl) sulfonyl) isoindoline
The first step is as follows:
dissolving compound 1a (2.84 g, 10.0 mmol), compound 5a (1.6 g, 10.0 mmol) and DIEA (1.9 g, 15.0 mmol) in dichloromethane (50 mL), reacting at room temperature, monitoring the reaction by TLC, adding water (50 mL) after the reaction to quench the reaction, drying the organic layer, filtering, concentrating, and separating by column chromatography to obtain a light yellow solid (compound 5 b) 2.5g with a yield of 61.1%;
the second step is that:
compound 5b (409 mg, 1.0 mmol), compound 1d (112 mg, 1.0 mmol), potassium carbonate (276 mg, 2.0 mmol), and tetratriphenylphosphine palladium (115 mg, 0.1 mmol) were dissolved in dioxane (30 mL) and water (10 mL), the reaction was stirred at 80 ℃, the reaction was monitored by TLC, after completion of the reaction, extraction was performed with ethyl acetate (50 mL × 2), the organic layer was concentrated, and column chromatography was performed to obtain 271mg of off-white solid (compound 5) with a yield of 68.3%. ESI (+) m/z = 398.1.
Example 6
5-aminocarbonyl-2- ((2-methoxy-4- (1H-pyrazol-4-yl) phenyl) sulfonyl) isoindoline
The first step is as follows:
dissolving compound 1a (2.84 g, 10.0 mmol), compound 6a (1.6 g, 10.0 mmol) and DIEA (1.9 g, 15.0 mmol) in dichloromethane (50 mL), reacting at room temperature, monitoring the reaction by TLC, adding water (50 mL) after the reaction to quench the reaction, drying the organic layer, filtering, concentrating, and separating by column chromatography to obtain a light yellow solid (compound 6 b) 2.2g with a yield of 53.8%;
the second step is that:
compound 6b (409 mg, 1.0 mmol), compound 1d (112 mg, 1.0 mmol), potassium carbonate (276 mg, 2.0 mmol), and tetratriphenylphosphine palladium (115 mg, 0.1 mmol) were dissolved in dioxane (30 mL) and water (10 mL), the reaction was stirred at 80 ℃, the reaction was monitored by TLC, after completion of the reaction, extraction was performed with ethyl acetate (50 mL × 2), the organic layer was concentrated, and column chromatography was performed to obtain 285mg of a white solid (compound 6), with a yield of 71.6%. ESI (+) m/z = 399.1.
Example 7
5-trifluoromethyl-2- ((2-methoxy-4- (1H-pyrazol-4-yl) phenyl) sulfonyl) isoindoline
The first step is as follows:
dissolving compound 1a (2.84 g, 10.0 mmol), compound 7a (1.9 g, 10.0 mmol) and DIEA (1.9 g, 15.0 mmol) in dichloromethane (50 mL), reacting at room temperature, monitoring the reaction by TLC, adding water (50 mL) after the reaction to quench the reaction, drying the organic layer, filtering, concentrating, and separating by column chromatography to obtain a light yellow solid (compound 7 b) 2.6g with a yield of 59.8%;
the second step is that:
compound 7b (434 mg, 1.0 mmol), compound 1d (112 mg, 1.0 mmol), potassium carbonate (276 mg, 2.0 mmol), and palladium tetratriphenylphosphine (115 mg, 0.1 mmol) were dissolved in dioxane (30 mL) and water (10 mL), the reaction was stirred at 80 ℃ and monitored by TLC, after completion of the reaction, extracted with ethyl acetate (50 mL × 2), the organic layer was concentrated, and column chromatography gave 225mg of a white solid (compound 7) in 53.2% yield. ESI (+) m/z = 424.1.
Example 8
4-methoxy-2- ((2-methoxy-4- (1H-pyrazol-4-yl) phenyl) sulfonyl) isoindoline
The first step is as follows:
dissolving compound 1a (2.84 g, 10.0 mmol), compound 8a (1.5 g, 10.0 mmol) and DIEA (1.9 g, 15.0 mmol) in dichloromethane (50 mL), reacting at room temperature, monitoring the reaction by TLC, adding water (50 mL) after the reaction to quench the reaction, drying the organic layer, filtering, concentrating, and separating by column chromatography to obtain a light yellow solid (compound 8 b) 2.8g with a yield of 70.5%;
the second step is that:
compound 8b (397 mg, 1.0 mmol), compound 1d (112 mg, 1.0 mmol), potassium carbonate (276 mg, 2.0 mmol), and tetratriphenylphosphine palladium (115 mg, 0.1 mmol) were dissolved in dioxane (30 mL) and water (10 mL), the reaction was stirred at 80 ℃, monitored by TLC, extracted with ethyl acetate (50 mL × 2) after completion of the reaction, the organic layer was concentrated, and column chromatography gave 248mg of a white solid (compound 8) in 64.4% yield. ESI (+) m/z = 386.1.
Example 9
4-aminocarbonyl-2- ((2-methoxy-4- (1H-pyrazol-4-yl) phenyl) sulfonyl) isoindoline
The first step is as follows:
dissolving compound 1a (2.84 g, 10.0 mmol), compound 9a (1.6 g, 10.0 mmol) and DIEA (1.9 g, 15.0 mmol) in dichloromethane (50 mL), reacting at room temperature, monitoring the reaction by TLC, adding water (50 mL) after the reaction to quench the reaction, drying the organic layer, filtering, concentrating, and separating by column chromatography to obtain a light yellow solid (compound 9 b) 2.3g with a yield of 56.1%;
the second step is that:
compound 9b (410 mg, 1.0 mmol), compound 1d (112 mg, 1.0 mmol), potassium carbonate (276 mg, 2.0 mmol), and tetratriphenylphosphine palladium (115 mg, 0.1 mmol) were dissolved in dioxane (30 mL) and water (10 mL), the reaction was stirred at 80 ℃, the reaction was monitored by TLC, after completion of the reaction, extraction was performed with ethyl acetate (50 mL × 2), the organic layer was concentrated, and column chromatography was performed to obtain 208mg of a white solid (compound 9), with a yield of 52.3%. ESI (+) m/z = 399.1.
Example 10
4-fluoro-2- ((2-methoxy-4- (1H-pyrazol-4-yl) phenyl) sulfonyl) isoindoline
The first step is as follows:
dissolving compound 1a (2.84 g, 10.0 mmol), compound 10a (1.4 g, 10.0 mmol) and DIEA (1.9 g, 15.0 mmol) in dichloromethane (50 mL), reacting at room temperature, monitoring the reaction by TLC, adding water (50 mL) after the reaction to quench the reaction, drying the organic layer, filtering, concentrating, and separating by column chromatography to obtain a light yellow solid (compound 10 b) 2.0g with a yield of 51.9%;
the second step is that:
compound 10b (385 mg, 1.0 mmol), compound 1d (112 mg, 1.0 mmol), potassium carbonate (276 mg, 2.0 mmol), tetrakistriphenylphosphine palladium (115 mg, 0.1 mmol) were dissolved in dioxane (30 mL) and water (10 mL), the reaction was stirred at 80 ℃ and monitored by TLC, after completion of the reaction, extraction was performed with ethyl acetate (50 mL × 2), the organic layer was concentrated, and column chromatography gave 226mg of a white solid (compound 10) with a yield of 60.6%. ESI (+) m/z = 374.1.
Example 11
5- (3-methoxy-4- ((5-methoxyisoindolin-2-yl) sulfonyl) phenyl) -1H-indazole
Compound 1c was synthesized according to the procedure of the first step in example 1.
Compound 1c (397 mg, 1.0 mmol), compound 11a (162 mg, 1.0 mmol), potassium carbonate (276 mg, 2.0 mmol), tetrakistriphenylphosphine palladium (115 mg, 0.1 mmol) were dissolved in dioxane (30 mL) and water (10 mL), the reaction was stirred at 80 ℃, monitored by TLC, after completion of the reaction, extracted with ethyl acetate (50 mL × 2), the organic layer was concentrated, and column chromatography gave 255mg of white solid (compound 11) in 58.6% yield, ESI (+) m/z = 436.1.
Example 12
5- (3-methoxy-4- ((5-fluoroisoindolin-2-yl) sulfonyl) phenyl) -1H-indazole
Compound 2b was synthesized according to the procedure of the first step in example 2.
Compound 2b (385 mg, 1.0 mmol), compound 11a (162 mg, 1.0 mmol), potassium carbonate (276 mg, 2.0 mmol), and tetratriphenylphosphine palladium (115 mg, 0.1 mmol) were dissolved in dioxane (30 mL) and water (10 mL), the reaction was stirred at 80 ℃, the reaction was monitored by TLC, after completion of the reaction, extraction was performed with ethyl acetate (50 mL × 2), the organic layer was concentrated, and column chromatography was performed to obtain 278mg of a white solid (compound 12) with a yield of 65.7%. ESI (+) m/z = 424.1.
Example 13
5- (3-methoxy-4- ((5-chloroisoindolin-2-yl) sulfonyl) phenyl) -1H-indazole
Compound 3b was synthesized according to the procedure of the first step in example 3.
Compound 3b (400 mg, 1.0 mmol), compound 11a (162 mg, 1.0 mmol), potassium carbonate (276 mg, 2.0 mmol), and tetratriphenylphosphine palladium (115 mg, 0.1 mmol) were dissolved in dioxane (30 mL) and water (10 mL), the reaction was stirred at 80 ℃, the reaction was monitored by TLC, after completion of the reaction, extraction was performed with ethyl acetate (50 mL × 2), the organic layer was concentrated, and column chromatography was performed to obtain 278mg of a white solid (compound 13) in a yield of 63.3%. ESI (+) m/z = 440.1.
Example 14
5- (3-methoxy-4- ((5-dimethylaminoindolin-2-yl) sulfonyl) phenyl) -1H-indazole
Compound 4b was synthesized according to the procedure of the first step in example 4.
Compound 4b (410 mg, 1.0 mmol), compound 11a (162 mg, 1.0 mmol), potassium carbonate (276 mg, 2.0 mmol), and palladium tetratriphenylphosphine (115 mg, 0.1 mmol) were dissolved in dioxane (30 mL) and water (10 mL), the reaction was stirred at 80 ℃ and monitored by TLC, after completion of the reaction, extracted with ethyl acetate (50 mL × 2), the organic layer was concentrated, and column chromatography gave 240mg of a white solid (compound 14) in 53.6% yield. ESI (+) m/z = 449.2.
Example 15
5- (3-methoxy-4- ((5-acetylisoindolin-2-yl) sulfonyl) phenyl) -1H-indazole
Compound 5b was synthesized according to the procedure of the first step in example 5.
Compound 5b (409 mg, 1.0 mmol), compound 11a (162 mg, 1.0 mmol), potassium carbonate (276 mg, 2.0 mmol), and tetratriphenylphosphine palladium (115 mg, 0.1 mmol) were dissolved in dioxane (30 mL) and water (10 mL), the reaction was stirred at 80 ℃, the reaction was monitored by TLC, after completion of the reaction, extraction was performed with ethyl acetate (50 mL × 2), the organic layer was concentrated, and column chromatography was performed to obtain 254mg of a white solid (compound 15) with a yield of 56.8%. ESI (+) m/z = 448.1.
Example 16
5- (3-methoxy-4- ((5-aminocarbonylisoindolin-2-yl) sulfonyl) phenyl) -1H-indazole
Compound 6b was synthesized according to the procedure of the first step in example 6.
Compound 6b (409 mg, 1.0 mmol), compound 11a (162 mg, 1.0 mmol), potassium carbonate (276 mg, 2.0 mmol), and tetratriphenylphosphine palladium (115 mg, 0.1 mmol) were dissolved in dioxane (30 mL) and water (10 mL), the reaction was stirred at 80 ℃, the reaction was monitored by TLC, after completion of the reaction, extraction was performed with ethyl acetate (50 mL × 2), the organic layer was concentrated, and column chromatography was performed to obtain 282mg of a white solid (compound 16) with a yield of 62.8%. ESI (+) m/z = 449.1.
Example 17
5- (3-methoxy-4- ((5-trifluoromethyl isoindolin-2-yl) sulfonyl) phenyl) -1H-indazole
Compound 7b was synthesized following the procedure of the first step in example 7.
Compound 7b (434 mg, 1.0 mmol), compound 11a (162 mg, 1.0 mmol), potassium carbonate (276 mg, 2.0 mmol), and tetratriphenylphosphine palladium (115 mg, 0.1 mmol) were dissolved in dioxane (30 mL) and water (10 mL), the reaction was stirred at 80 ℃, monitored by TLC, extracted with ethyl acetate (50 mL × 2) after completion of the reaction, the organic layer was concentrated, and column chromatography gave 269mg of a white solid (compound 17) in 56.9% yield. ESI (+) m/z = 474.1.
Biological evaluation
In this example, GSK269962 is an internal control compound by detecting the inhibition effect of the compounds 1 to 17 prepared in the examples 1 to 17 on ROCK1(ROCK2) kinase.
The experimental method comprises the following steps:
diluting the compound with dimethyl sulfoxide (DMSO) to 10 different concentrations for use;
buffer solution: 40mM Tris pH 7.5, 20mM MgCl2, 0.1% BSA, 50. mu.M DTT;
adding 10 μ L of 2.5 × 0.1 μ g/mL ROCK1(ROCK2) working solution into a 96-well plate;
adding 5 μ L of 5 × compound solution to a 96-well plate, mixing, and incubating at 25 deg.C for 10 min;
add 10. mu.L 2.5X 37.5. mu.g/mL S6K substrate and 12.5. mu.M ATP mix working solution, incubate 60 minutes at 30 ℃;
adding 25 μ L of the reaction mixture to another 96-well plate, adding 25 μ L of ADP-Glo reagent, mixing, incubating at 25 ℃ for 60 min, and terminating the reaction;
adding 40 mul of the mixed solution for terminating the reaction into 40 mul of the kinase detection reagent, mixing uniformly, and incubating for 40 minutes at 25 ℃;
reading Iummescence signal value, and calculating to obtain compound IC50. The test results were as follows:
as can be seen from the above table, compounds 1 to 17 all have certain inhibitory effects on ROCK1(ROCK2) kinase, wherein the IC of compound 1, compound 2, compound 3, compound 5, compound 6, compound 8, compound 9, compound 10, compound 11, compound 12, compound 16 and compound 17 on ROCK150Values less than 10 nM; IC of Compound 2, Compound 3, Compound 5, Compounds 11 to 15 against ROCK250Values were less than 10 nM.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents and improvements made within the spirit and principle of the present invention are intended to be included within the scope of the present invention.
Claims (10)
1. A compound having the structure of formula I:
wherein R is1Is methoxy, fluoro, chloro, bromoCyano, aminocarbonyl, acetyl, dimethylamino, trifluoromethyl,
R21H-indazol-5-yl and 1H-pyrazol-4-yl.
2. A process for the preparation of a compound having the structure of formula i, or a pharmaceutically acceptable salt thereof, as claimed in claim 1, comprising the steps of:
and (3) synthesizing an intermediate IV:
reacting a compound II with a structure shown in a formula II and a compound III with a structure shown in a formula III in a first solvent in the presence of a first base at a first reaction temperature to generate an intermediate IV with a structure shown in a formula IV;
synthesis of Compound I:
and (3) carrying out coupling reaction on the intermediate IV and the compound V with the structure of the formula V in a second solvent in the presence of a second base under the action of a catalyst at a second reaction temperature to generate the compound with the structure of the formula I.
3. The method according to claim 2, wherein the first solvent is at least one of tetrahydrofuran, dioxane, toluene, N-dimethylformamide, dichloromethane, and acetonitrile;
and/or the second solvent is any one of dioxane, N-dimethylformamide, toluene, dioxane/water and glycol dimethyl ether.
4. The method of claim 2, wherein the first reaction temperature is 20 to 100 ℃;
and/or the second reaction temperature is 40-120 ℃.
5. The method of claim 2, wherein the first base is at least one of triethylamine, N-diisopropylethylamine, N-methylmorpholine, potassium carbonate, cesium carbonate, and sodium carbonate;
and/or the second base is at least one of cesium carbonate, sodium tert-butoxide, potassium carbonate, sodium acetate and potassium phosphate.
6. The method according to claim 2, wherein the catalyst is at least one of tetrakistriphenylphosphine palladium, palladium acetate, tris-dibenzylideneacetone dipalladium, and 1,1' -bis (diphenylphosphino) ferrocene dichloropalladium.
7. A pharmaceutical composition comprising a compound having the structure of formula i as claimed in claim 1 or a pharmaceutically acceptable salt thereof.
8. Use of a compound having the structure of formula i or a pharmaceutically acceptable salt thereof according to claim 1 or a pharmaceutical composition according to claim 7 as a ROCK inhibitor in the manufacture of a medicament for the treatment of a tumor, a cardiovascular disease, a neurological disease, a fibrotic disease.
9. The use according to claim 8, wherein the tumor is selected from the group consisting of:
skin cancer, bladder cancer, ovarian cancer, breast cancer, stomach cancer, prostate cancer, colon cancer, lung cancer, bone cancer, brain cancer, rectal cancer, esophageal cancer, tongue cancer, kidney cancer, cervical cancer, uterine body cancer, testicular cancer, urinary cancer, astrocytic cancer, meningioma, hodgkin's lymphoma, non-hodgkin's lymphoma, acute lymphatic leukemia, chronic lymphatic leukemia, acute myeloid leukemia, chronic myeloid leukemia, adult T-cell leukemia lymphoma, hepatocellular carcinoma, multiple myeloma, chondrosarcoma, sarcoma, fibrosarcoma.
10. The compound of claim 1 having the structure of formula i or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of compounds having the structure:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111637054.5A CN113980003B (en) | 2021-12-30 | 2021-12-30 | 2- ((2-methoxyphenyl) sulfonyl) isoindoline compound and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111637054.5A CN113980003B (en) | 2021-12-30 | 2021-12-30 | 2- ((2-methoxyphenyl) sulfonyl) isoindoline compound and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113980003A CN113980003A (en) | 2022-01-28 |
| CN113980003B true CN113980003B (en) | 2022-05-20 |
Family
ID=79734909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111637054.5A Active CN113980003B (en) | 2021-12-30 | 2021-12-30 | 2- ((2-methoxyphenyl) sulfonyl) isoindoline compound and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113980003B (en) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102005015040A1 (en) * | 2005-03-31 | 2006-10-05 | Sanofi-Aventis Deutschland Gmbh | Substituted tetrahydroisoquinolines as MMP inhibitors, process for their preparation and their use as medicament |
| CN110582491B (en) * | 2017-06-30 | 2023-09-29 | 北京泰德制药股份有限公司 | Rho-related protein kinase inhibitor, pharmaceutical composition containing Rho-related protein kinase inhibitor, and preparation method and application of Rho-related protein kinase inhibitor |
| ES2930804T3 (en) * | 2017-06-30 | 2022-12-22 | Beijing Tide Pharmaceutical Co Ltd | RHO-associated protein kinase inhibitor, pharmaceutical composition that comprises it, as well as method of preparation and use thereof |
| CN111116585B (en) * | 2019-12-31 | 2021-02-05 | 北京鑫开元医药科技有限公司 | Compound with c-MET kinase inhibitory activity, preparation method, composition and application |
| CN111732575B (en) * | 2020-08-03 | 2020-12-11 | 北京鑫开元医药科技有限公司 | N- (3- (pyrimidine-2-yl) phenyl) benzene sulfonamide derivative, pharmaceutical composition, preparation method and application |
| CN111892580B (en) * | 2020-09-29 | 2021-02-05 | 北京鑫开元医药科技有限公司 | 2-amino-4- (isoindoline-2-yl) pyrimidine-5-formamide derivative, preparation method and application |
-
2021
- 2021-12-30 CN CN202111637054.5A patent/CN113980003B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN113980003A (en) | 2022-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20200115583A (en) | 2H-indazole derivatives as CDK4 and CDK6 inhibitors and their therapeutic use | |
| CN111892580B (en) | 2-amino-4- (isoindoline-2-yl) pyrimidine-5-formamide derivative, preparation method and application | |
| EP4324833A1 (en) | Alkynylphenylbenzamide compound and use thereof | |
| CN116096372B (en) | EGFR inhibitor, preparation method and pharmaceutical application thereof | |
| CN111732575B (en) | N- (3- (pyrimidine-2-yl) phenyl) benzene sulfonamide derivative, pharmaceutical composition, preparation method and application | |
| TW479058B (en) | 2,7-substituted octahydro-pyrrolo[1,2-a]pyrazine derivatives | |
| CN111362925A (en) | 4-pyrimidine formamide compound, pharmaceutical composition, preparation method and application | |
| CN113999206A (en) | Isoquinoline-1, 3-diamine analogue, preparation method, pharmaceutical composition and application thereof | |
| CN113980003B (en) | 2- ((2-methoxyphenyl) sulfonyl) isoindoline compound and preparation method thereof | |
| CN111116585B (en) | Compound with c-MET kinase inhibitory activity, preparation method, composition and application | |
| CN114504574B (en) | 2- ((2-methoxyphenyl) sulfonyl) isoindoline compound pharmaceutical preparation and preparation method thereof | |
| CN109897036B (en) | Triazolopyridine compound and preparation method and application thereof | |
| WO2021073498A1 (en) | Egfr inhibitor, composition, and method for preparation thereof | |
| CN113264938B (en) | Imidazo [1,5-a ] pyrazine-8-amine compound, preparation method, pharmaceutical composition and application | |
| CN111718325A (en) | 2,4, 5-substituted pyrimidine compound and preparation method and application thereof | |
| CN112225742B (en) | Compound for inhibiting VEGFR activity, preparation method and application | |
| CN113493414B (en) | Deuterated substituted butenamide and preparation method and application thereof | |
| CN112279834B (en) | FGFR4 inhibitor, preparation method, pharmaceutical composition and application thereof | |
| TWI535724B (en) | New polymorphic forms of icotinib phosphate and uses thereof | |
| CN110407839B (en) | Preparation and application of triazole heterocyclic compound containing heteroaryl amide structure | |
| CN114533733A (en) | Isoquinoline-1, 3-diamine analogue pharmaceutical preparation and preparation method thereof | |
| JP2023505254A (en) | Preparation of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide way for | |
| CN112279836B (en) | N- (5-methyl-1H-pyrazol-3-yl) pyridine-2-amine compound and preparation method thereof | |
| CN113999244B (en) | 4H-pyrano [2,3-c ] pyridine-4-ketone compound and preparation method thereof | |
| CN112279810B (en) | 6-oxo-5, 6-dihydrophenanthridine-4-formamide compound, preparation method, pharmaceutical composition and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A 2- ((2-methoxyphenyl) sulfonyl) isoindoline compound and its preparation method Effective date of registration: 20230829 Granted publication date: 20220520 Pledgee: Industrial Bank Co.,Ltd. Beijing Pinggu Branch Pledgor: BEIJING XINKAIYUAN PHARMACEUTICAL TECHNOLOGY CO.,LTD. Registration number: Y2023110000364 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PP01 | Preservation of patent right |
Effective date of registration: 20240730 Granted publication date: 20220520 |
|
| PP01 | Preservation of patent right |